問卷

TPIDB > Study Site

Study Site



MacKay Memorial Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • mmhcto@gmail.com
  • Alice Huang
  • 25433535-2851
  • 104Taipei CityJhong ShanNo. 92, Sec. 2, Zhongshan N. Rd., Taipei City 10449, Taiwan

篩選

List

566Cases

2020-11-01 - 2027-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2020-12-01 - 2028-12-31

Phase I

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-12-01 - 2024-01-30

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting5Sites

2021-01-01 - 2024-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2021-03-31 - 2025-01-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2021-05-18 - 2023-12-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting5Sites

Terminated5Sites

2022-02-01 - 2029-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2026-07-01 - 2029-12-31

Phase II

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
  • Condition/Disease

    Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • Test Drug

    NS-863

Participate Sites
6Sites

Not yet recruiting1Sites

2026-07-01 - 2029-12-31

Phase II

Not yet recruiting
A phase 2, randomized, double-blind, placebo-controlled, dose-exploration trial was conducted to evaluate the efficacy and safety of oral NS-863 in participants with pulmonary arterial hypertension (PAH).
  • Condition/Disease

    Pulmonary hypertension

  • Test Drug

    NS-863

Participate Sites
5Sites

Not yet recruiting1Sites

2022-04-01 - 2028-09-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting8Sites